Beam Therapeutics. has filed a patent for adenosine base editors with increased efficiency for altering mutations associated with Glycogen Storage Disease Type 1a (GSD1a). The claim specifies the amino acid sequence of the adenosine deaminase variant required for the editing process. GlobalData’s report on Beam Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Beam Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Beam Therapeutics, CRISPR genome editing was a key innovation area identified from patents. Beam Therapeutics's grant share as of January 2024 was 3%. Grant share is based on the ratio of number of grants to total number of patents.

Adenosine base editors for glycogen storage disease type 1a

Source: United States Patent and Trademark Office (USPTO). Credit: Beam Therapeutics Inc

A recently filed patent (Publication Number: US20230383277A1) discloses claims related to adenosine deaminase variants and their use in base editor systems for treating genetic diseases. The claims detail specific amino acid sequences and combinations of alterations in adenosine deaminase variants, along with fusion proteins or complexes comprising these variants. The patent also covers methods for correcting single nucleotide polymorphisms associated with genetic diseases, such as Glycogen Storage Disease Type 1a, using the disclosed base editor systems. Additionally, the patent includes claims related to vectors, cells, compositions, kits, and formulations comprising the adenosine deaminase variants and base editor systems for therapeutic applications.

The patent claims highlight the potential of adenosine deaminase variants in base editor systems for precise genetic editing and correction of single nucleotide polymorphisms linked to genetic diseases. By utilizing specific amino acid sequences and combinations of alterations in these variants, the patent aims to provide targeted and effective treatments for conditions like Glycogen Storage Disease Type 1a. The inclusion of fusion proteins, complexes, and guide polynucleotides in the claims underscores the comprehensive approach towards genetic editing and disease treatment outlined in the patent. Overall, the patent presents a detailed framework for utilizing adenosine deaminase variants in base editor systems for therapeutic interventions, offering a promising avenue for addressing genetic disorders at the molecular level.

To know more about GlobalData’s detailed insights on Beam Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies